Defence Therapeutics talks precision drug delivery

Executive Summary

• Defence Therapeutics Inc. has officially repositioned its corporate strategy to focus exclusively on being a precision intracellular drug-delivery company.
• The core of this new strategy is the proprietary "Accum" platform, which is designed to enhance the intracellular delivery of complex cancer biologics, specifically aiming to increase therapeutic potency while reducing toxicity.
• The company will pursue a dual strategy combining internal R&D programs with strategic partnerships across the biotech and pharmaceutical sectors to advance assets such as antibody-drug conjugates (ADCs) and radiopharmaceuticals.

Key Details

• Strategic Focus: Shift to a "precision intracellular drug-delivery" company model.
• Core Technology: The "Accum" platform is highlighted as the central asset, designed to solve challenges in effective intracellular delivery by enhancing cellular uptake and payload release.
• Therapeutic Goals: The platform aims to increase therapeutic potency at lower doses, potentially reducing toxicity and improving patient access to advanced cancer treatments.
• Target Modalities: The strategy specifically targets the enhancement of existing and next-generation assets, including:
  • Antibody-drug conjugates (ADCs)
  • Radiopharmaceuticals
  • Other complex biologics
• Development Approach: A dual strategy involving:
  • Internal R&D programs
  • Strategic partnerships with pharma and biotech companies
• Clinical Vision: The goal is to transform therapies traditionally used in later lines of treatment into safer, more effective first-line treatment options.
• Executive Commentary: CEO Sebastien Plouffe stated the focus is to "solve drug delivery at the cellular level" to create optimal value for partners and better outcomes for patients.

Notable Quotes

• "Our focus is clear: solve drug delivery at the cellular level so cancer therapies, whether developed by Defence or by our partners, can reach their full potential," said Sebastien Plouffe, chief executive officer of Defence Therapeutics.
• "Accum is designed to create optimal value for partners while ultimately delivering better outcomes for patients."